Relmada (RLMD) CEO Reports Open-Market Purchases Totalling 265,976 Shares

Rhea-AI Filing Summary

Sergio Traversa, CEO and Director of Relmada Therapeutics, Inc. (RLMD), reported open-market purchases totaling 265,976 shares across three days, increasing his beneficial ownership to 1,000,000 shares. The Form 4 shows purchases on 08/26/2025 (80,545 shares at a weighted-average price of $0.62), 08/27/2025 (129,455 shares at $0.67), and 08/28/2025 (55,976 shares at $0.74). The filing explains each line represents aggregated open-market trades executed over price ranges: $0.61–$0.65, $0.65–$0.69, and $0.68–$0.79 respectively. All reported holdings are direct and the form is signed by the reporting person.

Positive

• CEO and Director purchased shares in open-market transactions totaling 265,976 shares
• Beneficial ownership increased to 1,000,000 shares, disclosed as direct ownership
• Form 4 includes weighted-average prices and explicit price ranges for aggregated trades
• Filing is signed by the reporting person, indicating formal compliance

Negative

• None.

Insights

Securities Analyst

TL;DR: CEO made material open-market purchases totaling 265,976 shares, bringing direct holdings to 1,000,000 shares.

The transactions are disclosed as open-market purchases across three consecutive dates and are reported with weighted-average prices and ranges, which is standard for aggregated trades. The aggregate increase to 1,000,000 shares is explicit and the reporting form indicates direct ownership. From a disclosure and compliance standpoint the filing is complete: transaction codes, prices, aggregate amounts, and an explanation of price ranges are provided, and the form is signed. The filing does not provide cash amounts paid in aggregate or any intent commentary, so financial impact must be assessed against external market and ownership context not contained here.

Corporate Governance Expert

TL;DR: Insider purchases by the CEO are clearly reported and raise governance transparency but offer no forward guidance.

The Form 4 indicates the reporting person is both a director and the CEO and that all reported holdings are direct. The filing follows Form 4 norms by disclosing transaction codes, weighted-average prices, and the price ranges for the aggregated trades. The signature and explanatory footnotes enhance traceability. The document contains no amendments or additional arrangements (e.g., 10b5-1 plan checkbox is not marked), so there is no further disclosure about prearranged trading plans. Material governance facts are documented, but implications for strategy or compensation are not included in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TRAVERSA SERGIO

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2025		P		80,545(1)	A	$0.62(2)	814,569	D
Common Stock	08/27/2025		P		129,455(1)	A	$0.67(3)	944,024	D
Common Stock	08/28/2025		P		55,976(1)	A	$0.74(4)	1,000,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

2. Purchase prices range from $0.61 to $0.65 per share, inclusive.

3. Purchase prices range from $0.65 to $0.69 per share, inclusive.

4. Purchase prices range from $0.68 to $0.79 per share, inclusive.

	/s/ Sergio Traversa	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Sergio Traversa report on the Form 4 for RLMD?

He reported three open-market purchases totaling 265,976 shares on 08/26/2025, 08/27/2025, and 08/28/2025

How many shares does Sergio Traversa beneficially own after these transactions?

He beneficially owns 1,000,000 shares following the reported transactions

What prices were disclosed for the insider purchases on the Form 4?

Weighted-average prices reported: $0.62 on 08/26/2025, $0.67 on 08/27/2025, and $0.74 on 08/28/2025; price ranges are $0.61–$0.65, $0.65–$0.69, and $0.68–$0.79 respectively

What is the reporting person’s relationship to Relmada Therapeutics (RLMD)?

The reporting person is both a Director and the Chief Executive Officer

Was the Form 4 signed and dated?

Yes; the form bears the signature of Sergio Traversa dated 08/28/2025